13. 多発性硬化症／視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details
臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02760056 (ClinicalTrials.gov) | June 6, 2016 | 5/4/2016 | Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study | Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study | Multiple Sclerosis | Drug: Liothyronine sodium;Drug: Placebo | Oregon Health and Science University | NULL | Completed | 18 Years | 50 Years | All | 15 | Phase 1 | United States |
| 2 | NCT02506751 (ClinicalTrials.gov) | July 2015 | 12/7/2015 | Open-label Study of Liothyronine in MS | A Phase 1b, Open-label Study to Evaluate the Safety and Tolerability of the Putative Remyelinating Agent, Liothyronine, in Individuals With MS | Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis, Secondary Progressive;Multiple Sclerosis, Primary Progressive | Drug: liothyronine | Johns Hopkins University | NULL | Completed | 18 Years | 58 Years | All | 20 | Phase 1 | United States |